This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoque, A. Articles by Hittelman, W. N. Search for Related Content PubMed PubMed Citation Articles by Hoque, A. Articles by Hittelman, W. N.

Quantitative Nuclear Morphometry by Image Analysis for Prediction of Recurrence of Ductal Carcinoma in Situ of the Breast¹

Departments of Clinical Cancer Prevention [A. H., S. M. L., D. M. W., S. R.], Experimental Therapeutics [I. V. B., W. N. H.], Biomathematics [E. N. A.], Pathology [N. S., A. S.], and Gynecologic Oncology [M. F.], University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030; Breast Cancer Consultation Service, St. Mary’s Medical School, San Francisco, California 91405 [M. D. L.]; Surgical Pathology, Jefferson University Hospital, Philadelphia, Pennsylvania 19107 [R. S.]; Department of Pathology, Tarzana Medical Center, Tarzana, California 91356 [W. J. C.]; Hoffman-La Roche Inc., Nutley, New Jersey 07110 [K. D.]; and Division of Cancer Prevention and Control, Chemoprevention Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 [G. J. K., C. W. B.]

Clinical management of ductal carcinoma in situ (DCIS) remains a challenge because significant proportions of patients experience recurrence after conservative surgical treatment. Unfortunately, it is difficult to prospectively identify, using objective criteria, patients who are at high risk of recurrence and might benefit from additional treatment. We conducted a multi-institutional, collaborative case-control study to identify nuclear morphometric features that would be useful for identifying women with DCIS at the highest risk of recurrence. Tissue sections of archival breast tissue of 29 women with recurrent and 73 matched women with nonrecurrent DCIS were stained for DNA, and nuclei in the DCIS lesions were evaluated by image analysis. A clear correlation between mean fractal2_area (FA2) and nuclear grade was observed (P < 0.001), allowing an objective determination of nuclear grade. Several nuclear morphometric features, including mean and variance of variation of radius, mean area, mean and variance of frequency of high boundary harmonics (FQH), and variance in sphericity, were found to be useful in discriminating recurrent from nonrecurrent DCIS subjects. However, the nuclear features associated with recurrence differed between high- and low-grade lesions. For lesions with high FA2 (nuclear grade 3), mean variation of radius, mean FQH, and mean area alone yielded recurrence odds ratios of 4.55 [95% confidence interval (CI) 0.45–45.96], 3.86 (95% CI, 0.88–16.98), 2.90 (95% CI, 0.31–27.2), respectively. Using a summed feature model, high-FA2 lesions showing three poor prognostic features had an odds ratio of 15.63 (95% CI, 1.22–200), compared with those with zero or one poor prognostic feature. Lesions with low mean FA2 (nuclear grade 1 or 2) showing high variances in sphericity and FQH had an odds ratio of 7.71 (95% CI, 1.77–33.60). Addition of other features did not enhance the odds ratio or its significance. These results suggest that nuclear image analysis of DCIS lesions may provide an adjunctive tool to conventional pathological analysis, both for the objective assessment of nuclear grade and for the identification of features that predict patient outcome.

This article has been cited by other articles:

				S. E. Steigen, B. Straume, D. Turbin, A. K.W. Chan, S. Leung, T. O. Nielsen, and S. Lindal Clinicopathologic Factors and Nuclear Morphometry as Independent Prognosticators in KIT-positive Gastrointestinal Stromal Tumors J. Histochem. Cytochem., February 1, 2008; 56(2): 139 - 145. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]

				M. S. Pepe, H. Janes, G. Longton, W. Leisenring, and P. Newcomb Limitations of the Odds Ratio in Gauging the Performance of a Diagnostic, Prognostic, or Screening Marker Am. J. Epidemiol., May 1, 2004; 159(9): 882 - 890. [Abstract] [Full Text] [PDF]